Top Markets
Coin of the day
Compugen Ltd. Compugen Ltd.

Compugen Ltd.

CGEN
주식 순위 #36946
Compugen Ltd. is a clinical-stage biotechnology company engaged in the... Compugen Ltd. is a clinical-stage biotechnology company engaged in the discovery, development, and commercialization of innovative therapeutic candidates across Israel, the United States, and Europe. The company's primary focus is immuno-oncology, with a robust pipeline of investigational treatments. Key assets in their immuno-oncology portfolio include: COM701, an anti-PVRIG antibody, currently in Phase I clinical trials for the treatment of solid tumors. COM902, a therapeutic antibody targeting TIGIT, also in Phase I, being evaluated as a monotherapy in patients with advanced malignancies. Bapotulimab, an antibody designed to target ILDR2, which is undergoing Phase I clinical study for solid tumors. AZD2936, a novel bispecific antibody that targets both TIGIT and PD-1, advancing through Phase I/II clinical studies in patients with advanced or metastatic non-small cell lung cancer. Beyond these clinical-stage programs, Compugen is also pursuing early-stage immuno-oncology research, with a particular emphasis on myeloid targets. The company maintains significant strategic alliances, including: A collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against Compugen's proprietary immune checkpoint regulators. A partnership with Bristol-Myers Squibb to assess the safety and tolerability of COM701 when combined with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo, in advanced solid tumor patients. An engagement with Johns Hopkins School of Medicine to explore novel T cell and myeloid checkpoint targets. A licensing agreement with AstraZeneca for the development of bispecific and multispecific immuno-oncology antibody products. A research collaboration with Johns Hopkins University focusing on myeloid research. Compugen Ltd. was founded in 1993 and is headquartered in Holon, Israel.
주가
$2.31
마지막 동기화: 2026-08-14
시가총액
$2.18M
변동 (1일)
-3.16%
변동 (1년)
57.79%
국가
IL
거래 Compugen Ltd. (CGEN)

카테고리

Compugen Ltd. (CGEN)의 주가 이력
최고 종가: $2.30 (2026-08-01 기준)

최저 종가: $1.56 (2002-08-01 기준)
Compugen Ltd.의 주가 이력 (2002 ~ 2026)
연간 주가 성과
연도 성과
2026 (TTM) 26.26%
2025 -2.77%
2024 29.85%
2023 33.11%
2022 -79.00%
2021 -66.79%
2020 129.28%
2019 99.35%
2018 11.15%
2017 -55.10%
2016 -15.79%
2015 -15.30%
2014 -10.13%
2013 75.91%
2012 8.18%
2011 8.07%
2010 24.89%
2009 613.45%
2008 -72.15%
2007 -34.57%
2006 -11.38%
2005 -36.97%
2004 -8.96%
2003 215.42%
2002 0.00%
유사 기업 또는 경쟁사의 주가
회사 주가 변동률 1년% 국가
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE